Second-quarter 2026 earnings, reported in early August, showed Eli Lilly extending its lead over Novo Nordisk in the obesity-drug market, with tirzepatide sales driving a sharp revenue jump while Novo's newer oral weight-loss pill and its next-generation CagriSema program both landed below Wall Street's expectations.
Lilly's Numbers
Eli Lilly reported second-quarter revenue of nearly $23 billion, up 48 percent year over year and above the roughly $20.6 billion analysts had projected. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, remained the company's primary growth driver and, by revenue, the best-selling drug in the world. Lilly's stock rose about 2 percent on the news, and the company raised its full-year revenue guidance to a range of $85 billion to $87 billion, up from its earlier $82 billion to $85 billion forecast.
Novo Nordisk's Numbers
Novo Nordisk's stock fell about 6 percent following its own earnings report. The company's oral semaglutide pill, marketed as an oral version of Wegovy, brought in roughly $494 million in the quarter, short of the $546 million analysts had expected. Foundayo, Lilly's competing oral GLP-1 pill (orforglipron), posted $98 million in sales, also slightly below the $104 million consensus estimate, suggesting the broader oral GLP-1 category is still ramping up more slowly than some forecasts assumed. Novo also narrowed its full-year sales guidance to a range of flat growth to a 6 percent decline, an improvement from its prior forecast of a 4 to 12 percent decline, but still reflecting a difficult year.
The CagriSema Setback
Adding to Novo's quarter, its CagriSema program underperformed tirzepatide in the REDEFINE 4 head-to-head trial reported earlier in the year, missing the statistical bar of non-inferiority on weight loss. That result, discussed in more detail elsewhere on this site, has weighed on investor confidence in CagriSema as Novo's next flagship weight-loss drug.
Why This Matters Beyond Wall Street
Earnings results aren't medical evidence, and a sales gap between two drugs says nothing about which is more appropriate for a given patient. But the competitive dynamics do matter for the broader peptide-therapy landscape: they influence how much each company invests in further trials, how aggressively they price and market their drugs, manufacturing capacity and, over time, insurance coverage negotiations. Novo Nordisk, whose Ozempic and Wegovy brands built the modern GLP-1 category, has steadily ceded market share to Lilly's tirzepatide-based products even as both companies continue to expand supply and pursue next-generation drugs like retatrutide and CagriSema.
The Oral-Pill Race Specifically
Both companies are chasing the same prize with their oral pills: an alternative to weekly injections that could expand the addressable market to patients who are hesitant about needles or want a simpler routine. The fact that both Novo's oral Wegovy and Lilly's Foundayo (orforglipron) came in slightly below analyst expectations in the same quarter suggests the oral category as a whole is ramping more slowly than some forecasts assumed, not that one company's pill is clearly outperforming the other's. Manufacturing capacity, insurance formulary placement, and pricing all factor into how quickly either oral drug scales, separate from the underlying clinical data.
The Bottom Line
Tirzepatide's commercial strength doesn't establish it as clinically superior for every patient, and individual response to any GLP-1, GIP, or amylin-based therapy varies. Patients and clinicians make treatment decisions based on individual health factors, side-effect profiles, and insurance coverage, not quarterly earnings reports. Anyone considering a GLP-1-class medication should discuss the specific approved options with a licensed physician rather than a company's market position.